A carregar...
Ra-223 Treatment for Bone Metastases in Castrate-Resistant Prostate Cancer: Practical Management Issues for Patient Selection
Bone metastases are common in men with metastatic castrate-resistant prostate cancer (mCRPC), occurring in 30% of patients within 2 years of castrate resistance and in >90% of patients over the disease course. There are 6 US Food and Drug Administration-approved therapies for mCRPC with demonstra...
Na minha lista:
| Publicado no: | Am J Clin Oncol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Lippincott Williams & Wilkins
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6445613/ https://ncbi.nlm.nih.gov/pubmed/30844849 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/COC.0000000000000528 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|